Últimas noticias sobre Bristol-Myers Squibb (NYSE:BMY) Bolsa

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Exclusives

Trading Ideas

LUCY

Descubre cinco acciones en auge según el Índice Stock Whisper de Benzinga. ¿Cuál será la próxima gran oportunidad?

Cinco acciones prometedoras que merecen atención según el Índice Stock Whisper

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Bristol-Myers Squibb Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to $70. Here&#8217;s<a href="https://www.benzinga.com/quote/BMY/news"> what you need to know</a>.
What To Know: The analyst's upgrade comes after increased confidence in several aspects of Bristol-Myers Squibb's business, particularly its pipeline and upcoming product launches. Tewari highlighted three key reasons for the upgrade.
Tewari believes Cobenfy (KarXT), a treatment for schizophrenia and bipolar disorder, is on track to become a $10 billion-plus drug. He is bullish on the drug&#8217;s launch in schizophrenia, as well as its potential in treating Alzheimer&#8217;s psychosis and bipolar disorder. He expects strong sales growth in the coming years, with a 2025 forecast of $215 million, significantly above consensus estimates.
The analyst expressed confidence that Milvexian, a drug in development for atrial fibrillation, could achieve positive results in non-inferiority trials, further supporting the company&#8217;s growth prospects. He also noted improved visibility on Bristol-Myers Squibb's financials, driven by positive momentum from recent product launches and growing clarity on cost control measures. As a result, he raised his earnings-per-share projections, expecting the company to reach EPS floor of $6 in the near future.
Additionally, the company's ongoing collaboration with Immatics N.V. remains intact, despite the recent termination of other partnership agreements, including the allogeneic and opt-in collaborations with BMS. While this move reflects ongoing portfolio prioritization efforts, the termination does not require Bristol-Myers Squibb to refund any of the upfront payments.
With a new price target of $70, Jefferies sees upside potential in Bristol-Myers Squibb's stock.
BMY Price Action: Bristol-Myers Squibb shares were up 0.14% at $55.86 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-1024x522.png" alt="" class="wp-image-694648" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er.png 1235w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42516580/ionq-quantum-computing-and-rigetti-computing-shares-are-soaring-monday-whats-going-on">IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What&#8217;s Going On?</a></li>
</ul>
Image Via Shutterstock.

News

Movers

Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$17.00</td>
<td>$167.5K</td>
<td>17.1K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$500.00</td>
<td>$29.9K</td>
<td>1.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$54.7K</td>
<td>6.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$180.00</td>
<td>$292.5K</td>
<td>6.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>VRDN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$22.50</td>
<td>$27.0K</td>
<td>458</td>
<td>599</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$580.00</td>
<td>$57.1K</td>
<td>475</td>
<td>250</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$80.00</td>
<td>$45.0K</td>
<td>14</td>
<td>99</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$40.00</td>
<td>$32.6K</td>
<td>615</td>
<td>25</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$25.00</td>
<td>$25.1K</td>
<td>42</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 2500 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $167.5K, with a price of $67.0 per contract. There were 17104 open contracts at this strike prior to today, and today 2970 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 38 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $788.0 per contract. There were 1381 open contracts at this strike prior to today, and today 2262 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 205 contract(s) at a $50.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $54.7K, with a price of $267.0 per contract. There were 6605 open contracts at this strike prior to today, and today 1828 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bearish, expiring in 760 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $292.5K, with a price of $11700.0 per contract. There were 6297 open contracts at this strike prior to today, and today 1688 contract(s) were bought and sold. 
• For VRDN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), we notice a call option trade that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 200 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $27.0K, with a price of $135.0 per contract. There were 458 open contracts at this strike prior to today, and today 599 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 56 contract(s) at a $580.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $1020.0 per contract. There were 475 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a call option trade with bullish sentiment. It expires in 32 day(s) on January 17, 2025. Parties traded 98 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $460.0 per contract. There were 14 open contracts at this strike prior to today, and today 99 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option trade with neutral sentiment. It expires in 95 day(s) on March 21, 2025. Parties traded 20 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $32.6K, with a price of $1630.0 per contract. There were 615 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be neutral, expiring in 151 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $25.1K, with a price of $2517.0 per contract. There were 42 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

PRAX

TEVA

VKTX

VRDN

9 Health Care Stocks With Whale Alerts In Today's Session

On December 12, 2024, Bristol Myers Squibb (&quot;BMS&quot;) notified Immatics N.V. (the &quot;Company&quot;) that, due to ongoing portfolio prioritization efforts within BMS, it has elected to terminate the collaboration agreement, dated June 1, 2022, between Celgene Switzerland LLC and Immatics US, Inc., relating to the development of allogeneic programs, and the opt-in agreement, dated April 28, 2023, between Celgene Switzerland LLC and Immatics GmbH, relating to a target under the parties&#39; multi-target TCR-T strategic collaboration. The terminations are effective as of March 12, 2025. The Company is not obligated to refund BMS any part of the $60 million upfront payment received under the collaboration agreement or the $15 million opt-in payment received under the opt-in agreement. The Company&#39;s collaboration with BMS under the 2019 multi-target TCR-T strategic collaboration agreement remains ongoing.

Biotech

Contracts

General

IMTX

Reported Friday, December 13, 2024, Bristol Myers Squibb Terminates Agreements with Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $490 to $494. Stifel analyst Paul Matteis maintained a Hold rating. Vertex Pharmaceuticals shares closed at $463.73 on Friday. See how other analysts view this stock.</li>
<li>Jefferies raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $63 to $70. Jefferies analyst Akash Tewari upgraded the stock from Hold to Buy. Bristol-Myers Squibb shares closed at $55.78 on Friday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer boosted the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $825 to $1,065. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Netflix shares closed at $918.87 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) price target from $155 to $150. Morgan Stanley analyst Joseph Moore maintained an Overweight rating. MKS Instruments shares settled at $112.55 on Friday. <a href="https://www.benzinga.com/quote/MKSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $320 to $450. Loop Capital analyst Anthony Chukumba maintained a Hold rating. Walmart shares closed at $446.04 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $92 to $82. Deutsche Bank analyst Krisztina Katai maintained a Buy rating. NIKE shares closed at $77.25 on Friday.  <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $122 to $135. Rosenblatt analyst Barton Crockett maintained a Buy rating. Disney shares closed at $113.34 on Friday. See how other analysts view this stock.</li>
<li>Mizuho cut the price target for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $137 to $134. Mizuho analyst Nitin Kumar maintained a Neutral rating. Exxon Mobil shares settled at $110.84 on Friday. <a href="https://www.benzinga.com/quote/XOM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised CNX Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) price target from $33 to $38. Mizuho analyst Nitin Kumar downgraded the stock from Neutral to Underperform. CNX Resources shares closed at $37.79 on Friday. <a href="https://www.benzinga.com/quote/CNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $400 to $515. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares closed at $436.23 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png" alt="" class="wp-image-693891" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126.png 1176w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

MKSI

NFLX

TSLA

VRTX

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

Jefferies analyst Akash Tewari upgrades Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from Hold to Buy and raises the price target from $63 to $70.

Upgrades

Jefferies Upgrades Bristol-Myers Squibb to Buy, Raises Price Target to $70

<figure class="table"> 
<table>
<tbody>
<tr>
<td> Termination of a Material Definitive Agreement</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
On January 7, 2022, Century Therapeutics, Inc. (the "Company") entered into a Research, Collaboration and License Agreement (the "Collaboration Agreement") with Bristol-Myers Squibb Company ("BMS") to collaborate on the research, development and commercialization of induced pluripotent stem cell derived, engineered natural killer cell and/or gamma delta T cell programs for hematologic malignancies.
&nbsp;
Following an internal corporate portfolio prioritization process, BMS notified the Company on December 12, 2024 that it would be terminating the Collaboration Agreement in its entirety without cause. The termination will be effective on March 12, 2025. The Company is encouraged by the scientific progress on the programs and will evaluate opportunities in acute myeloid leukemia and multiple myeloma in the context of the ongoing strategic review of Century's pre-clinical pipeline. Both parties will work together in accordance with the termination provisions of the Collaboration Agreement.

IPSC

Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma  In The Context Of The Ongoing Strategic Review Of Century's Pre-clinical Pipeline

Offerings

Bristol-Myers Squibb Co Files For Mixed Shelf; Size Not Disclosed

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Health Care

Media

AMGN

EXEL

GILD

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

Dividends

Bristol Myers Squibb Increases Quarterly Dividend From $0.60 To $0.62/Share

B of A Securities analyst Tim Anderson reinstates Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and announces $63 price target.

Initiation

B of A Securities Reinstates Neutral on Bristol-Myers Squibb, Announces $63 Price Target

Multiple analyses underscore durable efficacy and well-established safety profile of Breyanzi (lisocabtagene maraleucel; liso-cel) in leukemia and several types of lymphoma.
 &nbsp;

Bristol Myers Squibb Reports Results From 18 Presentations; Data Demonstrate Efficacy, Durability And Safety Of Currently Available Therapies In Blood Cancers

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that it has entered a Research Collaboration and Option Agreement with Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) to discover and develop novel miniprotein-based therapeutics utilizing AI Proteins' powerful discovery platform.
Under this collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize miniproteins against targets of interest to Bristol Myers Squibb. These de novo designed miniproteins, characterized by their small size and high affinity, have the potential to offer significant advantages over traditional antibody-based therapies, including improved tissue penetration and rapid clearance.

AI Proteins Enters A Research Collaboration And Option Agreement With Bristol Myers Squibb To Discover And Develop Novel Miniprotein-Based Therapeutics Utilizing AI Proteins' Powerful Discovery Platform.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.00%</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 72%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $73 on Nov. 12. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Bristol-Myers Squibb filed a lawsuit last week against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA&#8217;s rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png" alt="" class="wp-image-674099" style="width:737px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.61%</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Geoff Meacham maintained a Buy rating and cut the price target from $226 to $215 on Nov. 12. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 18, AbbVie secured European Commission approval for ELAHERE, first novel therapy for platinum-resistant ovarian cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"> latest ABBV new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png" alt="" class="wp-image-674101" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-768x708.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 4.75%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 80%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and lowered the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Patterson Companies will hold its fiscal 2025 second-quarter conference call on Thursday, Dec. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">PDCO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png" alt="" class="wp-image-674102" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-768x705.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42267284/this-analyst-with-85-accuracy-rate-sees-more-than-8-upside-in-crowdstrike-here-are-5-stock-picks-for-november-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In CrowdStrike &#8211; Here Are 5 Stock Picks For November From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ABBV

PDCO

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

On Monday, Purple Biotech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42262840/purple-biotech-reports-positive-final-results-from-randomized-phase-2-study-of-cm24-in-second-line" rel="noreferrer noopener">ductal adenocarcinoma (PDAC)</a>.
Purple Biotech stock is trading higher with a strong session volume of 9.7 million, compared to an average volume of 48.73K as per data from <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
The Phase 2 study evaluated CM24 in combination with Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) immune checkpoint inhibitor nivolumab plus stand-of-care (SoC) chemotherapy in second-line metastatic PDAC patients versus SoC chemotherapy alone.
In the intent-to-treat cohort population, the median overall survival rate was 7.92 months in the CM24 combo treatment arm versus 5.55 months in the chemo arm.
The median progression-free survival was 3.9 months versus 2.0 months.
The overall response rate was 25% versus 7%, and the disease control rate was 63% compared to 47% in the CM24 combo arm vs. chemo alone group.
A consistent and continuous decrease of CA19-9, a clinically validated PDAC biomarker, was observed in the experimental arm, reaching a median percentage reduction from baseline of approximately 80% vs. an increase of 40% in the control arm.&nbsp;
A biomarker-enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control, with a 79% reduction in the risk of death and a median overall survival improvement of 5.1 months.
Over 90% reduction in risk of progression or death was observed, with a median progression-free survival improvement of 2.9 months and improvement in the treatment arm over the control, resulting in an overall response rate of 50% vs. 0%.
The CM24+nivolumab+Nal/IRI/5FU/LV regimen was well tolerated. The most frequent treatment-emergent Grade 3 or higher adverse events were diarrhea, fatigue, and neutropenia.
Accordingly, no meaningful differences in safety and tolerability were observed between the experimental arm and the SoC arm.
Price Action: PPBT stock is up 54.1% at $5.17 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides" target="_blank" rel="noreferrer noopener">Biden Targets China With New Chip Restrictions, Nvidia Slides</a></li>
</ul>
Photo via Shutterstock.

Equities

PPBT

Why Is Purple Biotech Stock Trading Higher On Monday?

Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.
Recently, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) filed a lawsuit against a U.S. government agency over a contentious&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">disagreement about payment methods</a>.
The pharmaceutical giant contends the statute governing the program allows manufacturers to choose between rebate and discount pricing models and claims HRSA's decision undermines this flexibility.
The 340B Drug Pricing Program requires drug manufacturers to sell medications at reduced prices to eligible healthcare providers, known as "covered entities," under specific conditions.
Bristol-Myers has historically used the discount model, offering upfront price reductions. However, the company argues this approach has led to widespread program abuses, including violations of safeguards meant to prevent duplication with Medicaid Drug Rebate Program rebates and diversion of discounted drugs to ineligible recipients.
Bristol-Myers <a href="https://www.statnews.com/wp-content/uploads/2024/11/bristol-vs-hhs-hrsa-340b.pdf" target="_blank" rel="noreferrer noopener">claims</a> these issues are exacerbated by intermediaries such as commercial pharmacies and third-party administrators, who profit from price disparities.
Citing these abuses and insufficient enforcement by HHS, Bristol-Myers announced its intention in October 2024 to transition to a rebate model.
Under this system, covered entities would initially pay the commercial price and later receive a rebate to achieve the 340B price. Bristol-Myers argues this model, explicitly permitted by the 340B statute, would enhance program integrity by reducing opportunities for abuse.
Despite the statutory basis for both models, HRSA determined that Bristol-Myers' proposed shift to a rebate model was inconsistent with the 340B statute and required pre-approval.
Bristol-Myers asserts this decision unlawfully restricts manufacturers' statutory options, violates the Administrative Procedure Act, and represents arbitrary and capricious regulatory overreach.
The company further claims the decision is illogical and contradicts substantive due process principles by imposing irrational constraints.
Eli Lilly And Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has also filed a lawsuit against the HRSA. The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount <a href="https://www.benzinga.com/general/biotech/24/11/42002487/mounjaro-maker-eli-lilly-files-lawsuit-against-us-agency-over-drug-rebate-program" target="_blank" rel="noreferrer noopener">offerings to hospitals</a>.
BMY Price Action: Bristol-Myers Squibb stock is up 0.12% at $59.36&nbsp;at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42246190/whats-going-on-with-hub-cyber-security-stock-today" target="_blank" rel="noreferrer noopener">Hub Cyber Security Powers Up: Major Debt Reduction, Fresh Investment, Board Change &amp; More</a></li>
</ul>
Photo: Courtesy of Bristol Myers Squibb

Government

Large Cap

Legal

Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program

Over the weekend, Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.
Data were presented at the American College of Rheumatology 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42012040/bristol-myers-faces-renewed-67-billion-lawsuit-over-drug-approval-delays-amid-resolved-trustee-issue" rel="noreferrer noopener">Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue</a>
CC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell therapy that <a href="https://acrabstracts.org/abstract/a-phase-1-multicenter-open-label-study-to-establish-the-preliminary-tolerability-efficacy-pharmacokinetics-and-pharmacodynamics-of-cc-97540-bms-986353-a-cd19-directed-car-t-cell-therapy-manufa/" target="_blank" rel="noreferrer noopener">expresses</a> the CD19 CAR used in FDA-approved Breyanzi (lisocabtagene maraleucel, liso-cel) but is manufactured using the NEX-TTM process, to shorten manufacturing time, improve potency, and optimize phenotypic attributes of the CAR T cell product.
Patients received a single infusion of CC-97540 2–7 days after lymphodepleting chemotherapy (3 days fludarabine [30 mg/m2], cyclophosphamide [300 mg/m2]).
Patients were treated with 10 × 10 power 6&nbsp;or 25 × 10 power 6&nbsp;CAR+ T cells in the dose-escalation phase.
Results from the first patients indicate promising preliminary safety and efficacy of CC-97540 at low doses.
The data also show encouraging CAR T cell expansion and complete B cell depletion.
The abstract notes that CC-97540, a NEX-T investigational CD19 CAR T cell product, is a more potent cellular drug product than liso-cel and can be manufactured with a more rapid processing time and greater capacity.
Goldman Sachs writes that data from 15 patients across three disease indications demonstrates a robust and compelling profile thus far, a very encouraging safety profile, and a noteworthy preliminary efficacy across multiple clinically relevant domains.
The analyst writes that NEX-T has strong potential to become a key growth driver for the company. Although Goldman Sachs has not included revenue estimates yet due to its early stage, they see a possible multibillion-dollar total addressable market across various rheumatologic disease applications.
&#8220;Along with peer commercial stage CAR-T players, we see BMY as well positioned to capitalize on structural advantages,&#8221; the analyst writes.
William Blair writes, &#8220;While there are unanswered questions on the registrational path, commercial opportunity, and competitive landscape for CD19 therapies in severe autoimmune diseases, we believe this patient vignette highlights the transformative potential of CD19 CAR-T in this setting and will further drive patient interest in these programs.&#8221;
Price Action: BMY stock is up 0.63% at $56.58 at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42043124/twist-biosciences-q4-earnings-and-q1-guidance-surpass-expectations-stock-jumps" target="_blank" rel="noreferrer noopener">Twist Bioscience&#8217;s Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps</a></li>
</ul>

Analyst Color

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases

WIIM

Shares of pharmaceutical companies are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Last month, U.S. District Judge Jesse Furman of the U.S. District Court for the Southern District of New York dismissed a $6.4 billion lawsuit against issuer Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
The plaintiff, UMB Bank, had not been properly <a href="https://www.milbank.com/a/web/r333FErFizuVNYcVKYmE5F/law360-bristol-myers-win-offers-lessons-for-debt-security-holders.pdf" target="_blank" rel="noreferrer noopener">appointed</a> as the trustee for the securities and therefore lacked standing to sue on behalf of the directing holders.
The issue undermined the lawsuit, filed 17 months after Bristol Myers acquired Celgene for $80.3 billion in 2019.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock" rel="noreferrer noopener">Bristol-Myers Squibb&#8217;s $14 Billion Potential &#8211; Analyst Upgrades Stock</a>
UMB Bank NA filed suit against Bristol-Myers in 2021. The firm alleges that the company intentionally slow-rolled the approval process for a cancer drug to dodge paying $6.4 billion owed to former Celgene shareholders under a contingent value rights agreement.
On Thursday, Bristol Myers Squibb was again hit with a $6.7 billion lawsuit. The company allegedly delayed federal approval for three drugs to avoid paying former Celgene shareholders.
The case, filed by UMB Bank, claims the delay cost &#8220;contingent value rights&#8221; (CVR) holders an extra $9 per share in cash. The drugs involved include the cancer treatment Breyanzi.
In the third quarter of 2024, Breyanzi generated sales of $224 million, up from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">$92 million a year ago</a>.
Per Reuters, UMB resolved the appointment issue. The bank is now confirmed as trustee, allowing it to proceed with the lawsuit. The estimated liability has increased from $6.4 billion to $6.7 billion.
Price Action: BMY stock is down 0.19% at $58.39 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42008174/fda-to-revisit-regeneron-sanofis-dupixent-for-rare-skin-disease" target="_blank" rel="noreferrer noopener">FDA To Revisit Regeneron/Sanofi&#8217;s Dupixent For Rare Skin Disease</a></li>
</ul>
Image: Shutterstock

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue

The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation. The final EC decision is expected in January 2025.&nbsp;

Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval For Bristol Myers Squibb's Repotrectinib For Adult Patients With Ros1-positive Advanced Non-small Cell Lung Cancer And Adult And Pediatric Patients With Advanced Solid Tumors Expressing An Ntrk Gene Fusion

Wolfe Research analyst Alexandria Hammond initiates coverage on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Peer Perform Rating

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading... With healthcare companies investing their resources in drug development and the adoption of the latest technologies for improving patients' lives and enhancing the system, the healthcare industry is booming. New-age solutions and technologies allow people to live longer, healthier, more productive, and more independent lives.
Given this backdrop, it could be wise to invest in quality healthcare stocks Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), and Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>), which are revolutionizing patient care.
Revenue in the pharmaceuticals market is expected to reach $1.16 trillion in 2024. Further, the market is anticipated to exhibit growth at a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">CAGR of 4.7%</a>, resulting in a market volume of $1.45 trillion by 2029. In global comparison, the United States is expected to generate the highest revenue of $630.30 billion in 2024 with its advanced healthcare infrastructure and strong R&amp;D capabilities.
The healthcare sector is experiencing strong growth and is currently driven by medical advancements and the latest technologies. In recent times, technology has marked significant strides in healthcare, enabling health providers and hospitals to treat patients better and improve their lives with advanced equipment, systems, and new software.
Also, healthcare companies are investing aggressively in R&amp;D to develop the latest drugs and solutions to aid the current healthcare system. Over 44 new medicines have been <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approved by the U.S. FDA in 2024</a>, targeting conditions and diseases like non-small cell lung cancer, acute leukemia, metastatic breast cancer, and hypoparathyroidism.
Further, technologies like Artificial Intelligence (AI), telemedicine, 3D printing, virtual reality, robotics, and electronic health records are contributing to efficient operations and procedures, revolutionizing aspects like drug discovery, patient care, patient monitoring, and labor-related issues. Notably, the <a href="https://www.advamed.org/medical-device-industry-facts/#:~:text=Medical%20technology%20saves%20lives%2C%20improves,paying%20jobs%20across%20the%20country.">U.S. is the largest medical device market</a> globally, comprising over 40% of the global medtech market.
Given these factors, let's delve deeper into the fundamentals of the top <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> stocks, starting with the third choice.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells various healthcare sector products internationally. The company operates in the Innovative Medicine and MedTech segments. It provides products for various therapeutic areas, like immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.
On November 21, JNJ announced that Health Canada has issued a Notice of Compliance for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for treating adult patients with multiple myeloma who have received therapy and who are refractory to lenalidomide. With the approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen-targeted approved therapy.
The approval marks a major milestone for patients with multiple myeloma. Clinical trials have shown that CARVYKTI&#xAE; can significantly lower the risk of disease progression or death compared to the current standard of care.
On November 12, JNJ received the U.S. FDA approval for its OTTAVA&#x2122; robotic surgical system investigational device exemption (IDE), which allows the clinical trial to begin at U.S. sites. JNJ is building on its global portfolio of surgical technologies to advance OTTAVA and help hospitals provide robotic surgery benefits to more patients.
The system will benefit patients and surgeons and address the unmet needs that persist in robotic surgery.
During the third quarter that ended September 29, 2024, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> grew 5.2% from the year-ago value to $15.51 billion. The company's adjusted net earnings from continuing operations came in at $5.88 billion and $2.42 per share for the quarter, respectively.
Street expects JNJ's revenue for the fiscal year (ending December 2024) to increase 4.3% year-over-year to $88.79 billion, and its EPS for the same year is estimated to grow marginally year-over-year to $9.96. Further, the company has surpassed the consensus EPS estimates in each of the trailing four quarters.
JNJ's stock has soared 1.1% over the past six months and 2.1% over the past year to close the last trading session at $153.
JNJ's solid prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Quality, Stability, Sentiment, and Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, JNJ is ranked #13 in the list of 155 stocks.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to access additional JNJ ratings for Growth and Momentum.
Stock #2: Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK operates as a healthcare company globally. The company operates in two segments: Pharmaceutical and Animal Health. It offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands.
On December 3, MRK was granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) by the U.S. FDA for treating patients with advanced or metastatic nonsquamous non-small cell lung cancer with epidermal growth factor receptor mutations.
Sac-TMT is an investigational trophoblast cell-surface antigen 2-directed antibody-drug conjugate being developed in collaboration with Kelun-Biotech.
On November 22, MRK announced that the National Medical Products Administration (NMPA) in China approved its WELIREG&#xAE; (belzutifan), for the treatment of adult patients with von Hippel-Lindau (VHL) disease.
During the third quarter that ended September 30, 2024, MRK reported sales of $16.66 billion, up 4.4% year-over-year, and its income before taxes was $4.09 billion for the period. The company's non-GAAP net income and non-GAAP EPS came in at $3.98 billion and 1.57 for the quarter, respectively.
The consensus EPS estimate of $1.81 for the fourth quarter (ending December 2024) represents a 5943.9% improvement year-over-year. The consensus revenue estimate of $15.47 billion for the same quarter reflects a 5.8% increase from last year. Also, MRK topped the consensus revenue and EPS estimates in all four trailing quarters.
MRK's stock has plunged 3% over the past month to close the last trading session at $99.75.
MRK's bright outlook is reflected in its POWR Ratings. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
MRK has an A grade for Quality and a B for Stability and Value. MRK is ranked #6 out of 155 stocks in the Medical – Pharmaceuticals industry.
<a href="https://stocknews.com/stock/MRK/">Click here</a> to access MRK's other ratings for Growth, Momentum, and Sentiment.
Stock #1: Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>)
BMY discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company provides products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
On November 15, BMY received Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval for Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient.
On the same date, BMY received CHMP of the EMA recommended approval for repotrectinib, which is a next-generation tyrosine kinase inhibitor, for treating adult patients with ROS1-positive advanced non-small cell lung cancer and for treating adult and pediatric patients above 12 years of age with advanced solid tumors expressing a NTRK gene fusion.
BMY's total revenues increased 8.4% year-over-year to $11.89 billion for the third quarter that ended September 30, 2024. Its non-GAAP gross profit grew 6.6% from the year-ago value to $9.04 billion. Furthermore, non-GAAP net earnings attributable to BMS and EPS totaled $3.65 billion and $1.80 for the quarter, respectively.
Analysts expect BMY's revenue for the fourth quarter (ending December 2024) to increase marginally year-over-year to $11.54 billion, and its EPS is expected to be $1.47 for the ongoing quarter. Also, the company has topped the consensus revenue estimates in all of the trailing four quarters.
Shares of BMY have gained 31.7% over the past six months and 10.9% over the past year to close the last trading session at $56.65.
BMY's POWR Ratings reflect its robust outlook. BMY has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
The stock has an A grade for Growth. It also has a B grade for Quality, Stability, Sentiment, and Value. BMY has topped among the 155 stocks in the same industry.
<a href="https://stocknews.com/stock/BMY/">Click here</a> to access all BMY ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares were trading at $146.15 per share on Thursday afternoon, down $0.49 (-0.33%). Year-to-date, JNJ has declined -3.80%, versus a 28.50% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jnj-mrk-bmy-3-healthcare-innovators-revolutionizing-patient-care/>3 Healthcare Innovators Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Innovators Revolutionizing Patient Care

Bristol-Myers Squibb Company files for automatic mixed securities shelf

16:18 EST Bristol Myers (BMY) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving b...

Bristol Myers files automatic mixed securities shelf

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

8 Funds For Potential $5,000 Monthly Income And Financial Freedom

As previously reported, Jefferies upgraded Bristol Myers (BMY) to Buy from Hold with a price target of $70, up from $63. The firm thinks Cobenfy ca...

Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline

Jefferies upgraded Bristol Myers (BMY) to Buy from Hold with a $70 price target Published first on TheFly – the ultimate source for real-time, mark...

Bristol Myers upgraded to Buy from Hold at Jefferies

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Netflix, MongoDB downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Honeywell (HON) said it continues to e...

Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz

Bristol-Myers upgraded to buy by Jefferies

AAPL

ALLE

AMZN

APLO

ASPI

ASTH

AVGO

BBAI

BCPC

BIIB

BSVN

CABO

CARR

CBSH

CCBG

CINF

CNTM

COST

CPRI

CSCO

CSGS

ENSG

ENVX

EPRT

ERIE

ESOA

EVRG

EXPO

FRME

GOLF

GOOGL

INVH

JJSF

JKHY

KFRC

KLIC

LAND

LFST

MBWM

MCHP

MPLX

MSFT

MTCH

NDAQ

NRIM

NTAP

NVDA

ODFL

OFLX

OKTA

OLED

OTEX

PRGO

PRVA

QCOM

RBCAA

SAMG

SEIC

SMCI

STLD

SWBI

TCBK

UBCP

VCTR

VICI

WDFC

Screenshot 2024-02-29 at 7.16.11 PM

ATNM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Press Releases

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

Earnings

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Bristol Myers Squibb Announces Dividend Increase

CATX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Comments

Bristol-Myers Squibb

Noticias

Últimas noticias sobre Bristol-Myers Squibb (NYSE:BMY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL